169 related articles for article (PubMed ID: 32559817)
1. Real-world outcomes of advanced melanoma patients not represented in phase III trials.
van Zeijl MCT; Ismail RK; de Wreede LC; van den Eertwegh AJM; de Boer A; van Dartel M; Hilarius DL; Aarts MJB; van den Berkmortel FWPJ; Boers-Sonderen MJ; de Groot JB; Hospers GAP; Kapiteijn E; Piersma D; van Rijn RS; Suijkerbuijk KPM; Ten Tije AJ; van der Veldt AAM; Vreugdenhil G; Haanen JBAG; Wouters MWJM
Int J Cancer; 2020 Dec; 147(12):3461-3470. PubMed ID: 32559817
[TBL] [Abstract][Full Text] [Related]
2. Real-world Outcomes of First-line Anti-PD-1 Therapy for Advanced Melanoma: A Nationwide Population-based Study.
van Zeijl MCT; Haanen JBAG; Wouters MWJM; de Wreede LC; Jochems A; Aarts MJB; van den Berkmortel FWPJ; de Groot JWB; Hospers GAP; Kapiteijn EW; Piersma D; van Rijn RS; Suijkerbuijk KPM; Ten Tije AJ; van der Veldt AAM; Vreugdenhil G; van der Hoeven KJM; van den Eertwegh AJM
J Immunother; 2020 Oct; 43(8):256-264. PubMed ID: 32804914
[TBL] [Abstract][Full Text] [Related]
3. Real-world experience with pembrolizumab in patients with advanced melanoma: A large retrospective observational study.
Liu FX; Ou W; Diede SJ; Whitman ED
Medicine (Baltimore); 2019 Jul; 98(30):e16542. PubMed ID: 31348273
[TBL] [Abstract][Full Text] [Related]
4. Modeled Prognostic Subgroups for Survival and Treatment Outcomes in BRAF V600-Mutated Metastatic Melanoma: Pooled Analysis of 4 Randomized Clinical Trials.
Hauschild A; Larkin J; Ribas A; Dréno B; Flaherty KT; Ascierto PA; Lewis KD; McKenna E; Zhu Q; Mun Y; McArthur GA
JAMA Oncol; 2018 Oct; 4(10):1382-1388. PubMed ID: 30073321
[TBL] [Abstract][Full Text] [Related]
5. Pembrolizumab Utilization and Outcomes for Advanced Melanoma in US Community Oncology Practices.
Cowey CL; Liu FX; Black-Shinn J; Stevinson K; Boyd M; Frytak JR; Ebbinghaus SW
J Immunother; 2018; 41(2):86-95. PubMed ID: 29252916
[TBL] [Abstract][Full Text] [Related]
6. Efficacy, safety and factors associated with disease progression in patients with unresectable (stage III) or distant metastatic (stage IV) BRAF V600-mutant melanoma: An open label, non-randomized, phase IIIb study of trametinib in combination with dabrafenib.
Saiag P; Robert C; Grob JJ; Mortier L; Dereure O; Lebbe C; Mansard S; Grange F; Neidhardt EM; Lesimple T; Machet L; Bedane C; Maillard H; Dalac-Rat S; Nardin C; Szenik A; Denden A; Dutriaux C
Eur J Cancer; 2021 Sep; 154():57-65. PubMed ID: 34243078
[TBL] [Abstract][Full Text] [Related]
7. Outcomes of patients with solid tumour malignancies treated with first-line immuno-oncology agents who do not meet eligibility criteria for clinical trials.
Gan CL; Stukalin I; Meyers DE; Dudani S; Grosjean HAI; Dolter S; Ewanchuk BW; Goutam S; Sander M; Wells C; Pabani A; Cheng T; Monzon J; Morris D; Basappa NS; Pal SK; Wood LA; Donskov F; Choueiri TK; Heng DYC
Eur J Cancer; 2021 Jul; 151():115-125. PubMed ID: 33975059
[TBL] [Abstract][Full Text] [Related]
8. The combination of stereotactic radiosurgery with immune checkpoint inhibition or targeted therapy in melanoma patients with brain metastases: a retrospective study.
Martins F; Schiappacasse L; Levivier M; Tuleasca C; Cuendet MA; Aedo-Lopez V; Gautron Moura B; Homicsko K; Bettini A; Berthod G; Gérard CL; Wicky A; Bourhis J; Michielin O
J Neurooncol; 2020 Jan; 146(1):181-193. PubMed ID: 31836957
[TBL] [Abstract][Full Text] [Related]
9. Nivolumab for advanced melanoma: pretreatment prognostic factors and early outcome markers during therapy.
Nakamura Y; Kitano S; Takahashi A; Tsutsumida A; Namikawa K; Tanese K; Abe T; Funakoshi T; Yamamoto N; Amagai M; Yamazaki N
Oncotarget; 2016 Nov; 7(47):77404-77415. PubMed ID: 27764805
[TBL] [Abstract][Full Text] [Related]
10. Clinical outcomes of adjuvant nivolumab in resected stage III melanoma: comparison of CheckMate 238 trial and real-world data.
Moser JC; Bhatia S; Amin A; Pavlick AC; Betts KA; Du EX; Poretta T; Shelley K; Srinivasan S; Sakkal LA; Palaia J; Lobo M; Pe Benito M; Linton JA; Chen Y; Xu C; Yin L; Sundar M; Weber J
Cancer Immunol Immunother; 2024 May; 73(7):116. PubMed ID: 38713408
[TBL] [Abstract][Full Text] [Related]
11. Association of Performance Status With Survival in Patients With Advanced Non-Small Cell Lung Cancer Treated With Pembrolizumab Monotherapy.
Sehgal K; Gill RR; Widick P; Bindal P; McDonald DC; Shea M; Rangachari D; Costa DB
JAMA Netw Open; 2021 Feb; 4(2):e2037120. PubMed ID: 33570575
[TBL] [Abstract][Full Text] [Related]
12. Real-world survival of patients with advanced BRAF V600 mutated melanoma treated with front-line BRAF/MEK inhibitors, anti-PD-1 antibodies, or nivolumab/ipilimumab.
Moser JC; Chen D; Hu-Lieskovan S; Grossmann KF; Patel S; Colonna SV; Ying J; Hyngstrom JR
Cancer Med; 2019 Dec; 8(18):7637-7643. PubMed ID: 31677253
[TBL] [Abstract][Full Text] [Related]
13. Prognostic factors in metastatic melanoma: a pooled analysis of Eastern Cooperative Oncology Group trials.
Manola J; Atkins M; Ibrahim J; Kirkwood J
J Clin Oncol; 2000 Nov; 18(22):3782-93. PubMed ID: 11078491
[TBL] [Abstract][Full Text] [Related]
14. Representativeness of Phase III Trial for Osimertinib in Pretreated Advanced EGFR-Mutated Non-small-cell Lung Cancer Patients and Treatment Outcomes in Clinical Practice.
Lin L; Smit EF; de Langen AJ; van Balen DEM; Beijnen JH; Huitema ADR
Target Oncol; 2022 Jan; 17(1):53-59. PubMed ID: 34894319
[TBL] [Abstract][Full Text] [Related]
15. Pembrolizumab versus ipilimumab for advanced melanoma: final overall survival results of a multicentre, randomised, open-label phase 3 study (KEYNOTE-006).
Schachter J; Ribas A; Long GV; Arance A; Grob JJ; Mortier L; Daud A; Carlino MS; McNeil C; Lotem M; Larkin J; Lorigan P; Neyns B; Blank C; Petrella TM; Hamid O; Zhou H; Ebbinghaus S; Ibrahim N; Robert C
Lancet; 2017 Oct; 390(10105):1853-1862. PubMed ID: 28822576
[TBL] [Abstract][Full Text] [Related]
16. Vemurafenib in BRAF-mutant metastatic melanoma patients in real-world clinical practice: prognostic factors associated with clinical outcomes.
Schouwenburg MG; Jochems A; Leeneman B; Franken MG; van den Eertwegh AJM; Haanen JBAG; van Zeijl MCT; Aarts MJ; van Akkooi ACJ; van den Berkmortel FWPJ; Blokx WAM; de Groot JWB; Hospers GAP; Kapiteijn E; Koornstra RH; Kruit WH; Louwman MWJ; Piersma D; van Rijn RS; Suijkerbuijk KPM; Ten Tije AJ; Vreugdenhil G; Wouters MWJM; van der Hoeven JJM
Melanoma Res; 2018 Aug; 28(4):326-332. PubMed ID: 29750749
[TBL] [Abstract][Full Text] [Related]
17. Prognostic score for patients with advanced melanoma treated with ipilimumab.
Diem S; Kasenda B; Martin-Liberal J; Lee A; Chauhan D; Gore M; Larkin J
Eur J Cancer; 2015 Dec; 51(18):2785-91. PubMed ID: 26597444
[TBL] [Abstract][Full Text] [Related]
18. Prognostic factors for overall survival after radiosurgery for brain metastases from melanoma.
Marcus DM; Lowe M; Khan MK; Lawson DH; Crocker IR; Shelton JW; Melton A; Maynard N; Delman KA; Carlson GW; Rizzo M
Am J Clin Oncol; 2014 Dec; 37(6):580-4. PubMed ID: 23428955
[TBL] [Abstract][Full Text] [Related]
19. Pembrolizumab for advanced nonsmall cell lung cancer: Efficacy and safety in everyday clinical practice.
Ksienski D; Wai ES; Croteau N; Freeman AT; Chan A; Fiorino L; Brooks EG; Poonja Z; Fenton D; Geller G; Irons S; Lesperance M
Lung Cancer; 2019 Jul; 133():110-116. PubMed ID: 31200816
[TBL] [Abstract][Full Text] [Related]
20. Blood Predictive Biomarkers for Nivolumab in Advanced Melanoma.
Chasseuil E; Saint-Jean M; Chasseuil H; Peuvrel L; Quéreux G; Nguyen JM; Gaultier A; Varey E; Khammari A; Dréno B
Acta Derm Venereol; 2018 Apr; 98(4):406-410. PubMed ID: 29327065
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
